The text starts here.

News Release

FOR IMMEDIATE RELEASE
September 29, 2016

EISAI TO PRESENT LATEST DATA ON LENVATINIB AND ERIBULIN AT ESMO CONGRESS 2016

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima®/Kisplyx®, “lenvatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven®, “eribulin”) will be presented during the European Society for Medical Oncology (ESMO) Congress 2016, taking place in Copenhagen, Denmark, from October 7 - 11.

For lenvatinib, six abstract poster presentations (including health economics and outcome research data) are to be given at the meeting with the main presentations featuring the latest data from a Phase Ib trial of lenvatinib in combination with the immune checkpoint inhibitor pembrolizumab in patients with selected solid tumors as well as an analysis of the responses in specific metastases following treatment with lenvatinib from the results of the Phase III SELECT Study.

For eribulin, an abstract poster presentation on a subgroup analysis in leiomyosarcoma (LMS) patients from a Phase III study (Study 309) in patients with advanced liposarcoma (LPS) and LMS is also scheduled to be given at the meeting.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as to healthcare providers.

Major Eisai abstracts accepted for presentation at this year's ESMO meeting include:
ProductAbstract title and scheduled presentation date and time (local time)
Lenvatinib

Abstract No: 2038
Responses in Specific Metastases Following Treatment with Lenvatinib: Results from the Phase III SELECT Study
Poster Presentation | October 9 (Sun), 13:00-14:00
Lenvatinib

Abstract No: 1608
Phase II study of lenvatinib (LEN) in patients (pts) with RET fusion–positive adenocarcinoma of the lung
Poster Presentation | October 9 (Sun), 14:45-16:15
Lenvatinib

Abstract No: 1779
A Phase Ib Trial of lenvatinib plus pembrolizumab in patients with selected solid tumors

Poster Presentation | October 9 (Sun), 16:30-17:30
Lenvatinib

Abstract No: 2008
Lenvatinib mesilate enhanced antitumor activity of PD-1 blockade agent by potentiating a Th1 immune response
Poster Presentation | October 9 (Sun), 16:30-17:30
Lenvatinib

Abstract No: 1284
The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling
Poster Presentation | October 10 (Mon), 13:00-14:00
Lenvatinib

Abstract No: 2616
Understanding real world treatment patterns, healthcare resource utilization (HRU) and costs among metastatic renal cell carcinoma (mRCC) patients
Poster Presentation | October 9 (Sun), 13:00-14:00
Eribulin

Abstract No: 1879
Subgroup analysis in leiomyosarcoma (LMS) patients (pts) from a Phase III, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced Liposarcoma (LPS) and LMS
Poster Presentation | October 10 (Mon), 11:00-12:00

(Note) SELECT Study: Study of E7080 “LEnvatinib” in Differentiated Cancer of the Thyroid


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120